- Apogee Therapeutics CFO Jane Henderson reported sale of 2,000 common shares on April 1, 2026.
- Shares sold at weighted average prices of $84.46, $85.46.
- Henderson held 177,371 shares following reported transactions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-039708), on April 03, 2026, and is solely responsible for the information contained therein.
Comments